Progyny's chief executive, Pete Anevski, recently provided insights into the company's operational strategies during a discussion with KeyBanc healthcare analyst Scott Schoenhaus. The conversation focused on how Progyny approaches benefit usage patterns, its methods for predicting future trends, and the introduction of its new comprehensive insurance offering. This discussion followed the company's latest financial results and coincided with the final stages of its sales cycle and the onboarding of new clients.

During a recent conference, Progyny's CEO shared the company's evolving strategies regarding fertility benefit usage, predictive analytics, and the upcoming launch of its fully insured product, 'Progyny Select'. This initiative targets smaller businesses, with revenue anticipated to commence in 2027. The company emphasizes actual benefit utilization as a core metric, rather than just eligible member counts, and employs sophisticated data analysis for forecasting. Furthermore, the discussion highlighted the specific risk management protocols embedded within the 'Progyny Select' offering to ensure its stability and profitability in the market.

Understanding Fertility Benefit Utilization and Predictive Analysis

Progyny's CEO, Pete Anevski, highlighted that the company primarily focuses on the actual usage of its fertility benefits rather than the fluctuating numbers of eligible individuals. He explained that eligibility counts, while reported, are considered an outcome, not a primary driver of business strategy. Anevski emphasized the consistent historical utilization rate, which has remained stable within a narrow range, typically between 1.03% and 1.09%. This stability is a key factor in Progyny's strategic approach, underscoring why the company places less emphasis on reported eligibility figures compared to external observers. The company’s forecasting relies on extensive historical client data, industry benchmarks, and a detailed understanding of individuals' progress through their fertility journeys, ensuring precise revenue and utilization predictions.

The conversation further delved into how Progyny translates the initial engagement from a new group of clients into higher-revenue fertility treatments over time. Anevski elaborated on the quarterly reporting framework, noting that only a small fraction of individuals who begin with a consultation also start treatment within the same quarter. He explained that while the first quarter sees a high number of individuals commencing their fertility journey, the majority of treatment activities, which generate more substantial revenue, typically manifest in subsequent quarters. For instance, a retrieval cycle initiated in Q2 might lead to a transfer in Q3 or Q4, depending on personal timelines. The CEO also mentioned that some individuals undergo multiple retrievals before a transfer, with an approximate average of 1.8 retrievals per successful live birth, stressing that this figure is an estimate used for planning. Progyny’s forecasting models integrate factors like the proportion of new consultations versus active treatments, the duration of treatment cycles influenced by appointment scheduling, and seasonal patterns, which collectively enable robust prediction of future revenue and utilization trends.

Strategic Rollout of Progyny Select for Small Businesses

A significant part of the discussion revolved around Progyny Select, the company's new fully insured product designed for small group employers. Anevski detailed the market entry strategy, which involves leveraging established distribution channels that small businesses already use to acquire premium-funded medical plans. These channels include brokers, consultants affiliated with general agencies, professional employer organizations (PEOs), and existing payer relationships. The immediate goal is to enlist distributors and equip brokers with the necessary training in anticipation of the crucial fourth-quarter renewal season for small group plans, which typically renew annually. While the commercialization of Progyny Select is underway, both Schoenhaus and Anevski concurred that the product is expected to go live and begin generating revenue in 2027.

Regarding financial implications, Anevski clarified that the operational model for Progyny Select is predominantly commission-based, with commissions disbursed as revenue is realized. He acknowledged an initial investment in the company’s sales force and support personnel dedicated to collaborating with distributors and conducting training sessions, costs that are already factored into current financial projections. He stated that no variable expenses specifically tied to the product are anticipated for the current year. On the underwriting and risk management front, Progyny will draw upon its extensive historical data, including insights from smaller client groups, to underwrite the new product. Key design features to mitigate utilization risk include targeting small group employers exclusively, covering only IVF treatments while excluding elective egg freezing to enhance predictability, and implementing utilization management safeguards and lifetime dollar maximums for high-cost claimants. Anevski expressed confidence that as the fully insured risk pool expands to several hundred thousand lives, its behavior will align more closely with Progyny's broader business portfolio, despite potential early fluctuations in performance. The company also retains the flexibility to adjust premiums annually based on experience, mirroring the practices of wider medical plans, with an eye towards market competitiveness and maintaining the incremental premium as a modest proportion of an employer’s total healthcare expenditure.